NCT03477396: Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 70 Years and older (Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system (CNS) involvement unless they meet certain criteria- see trial for details

Comments are closed.

Up ↑